Matteo Marchetti
Overview
Explore the profile of Matteo Marchetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marchetti M, Haddad C, Luca A, Le Bloa M, Teres C, Domenichini G, et al.
J Cardiovasc Electrophysiol
. 2025 Mar;
PMID: 40065558
Background: Identification of persistent AF (PsAF) patients who may be cured with stand-alone pulmonary vein isolation (PVI) would allow more efficient ablation strategies. Intuitively, the benefit of PVI is expected...
2.
Baskaralingam A, Marchetti M, Solana-Munoz J, Teres C, Le Bloa M, Porretta A, et al.
J Interv Card Electrophysiol
. 2025 Feb;
PMID: 39969790
Background: Fibrillatory wave amplitude (fWA) on 12-lead ECG predicts the outcome of ablation in atrial fibrillation (AF). We hypothesized that changes in fWA following wide circumferential isolation of pulmonary veins...
3.
Tommasi O, Marchetti M, Tripepi M, Bigardi S, Incognito G, Tuninetti V, et al.
J Clin Med
. 2025 Jan;
14(2.
PMID: 39860407
Cancer immunotherapy through the use of PD-1/PD-L1 inhibitors have shown significant promise in endometrial carcinoma (EC), particularly in tumors with microsatellite instability (MSI) or mismatch repair deficiency (dMMR), present in...
4.
Marchetti M, Ferrari J, Vezzaro T, Masatti L, Tasca G, Maggino T, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685500
This study provides a comprehensive overview of the role of immunotherapy in the treatment of mismatch repair-deficient (MMRd) endometrial carcinomas. Immunotherapy has emerged as a transformative approach in the treatment...
5.
Spagnol G, Bigardi S, Zorzi M, Morotti M, Carollo M, Bruni G, et al.
J Clin Med
. 2024 Nov;
13(22).
PMID: 39598059
To analyze the role of PCI variation (Δ-PCI) before and after neoadjuvant chemotherapy (NACT) in an interval cytoreductive surgery (ICS) setting with the aim to propose a scoring model for...
6.
Spagnol G, Marchetti M, Carollo M, Bigardi S, Tripepi M, Facchetti E, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594745
Objective: We aimed to compare the clinical utility and diagnostic accuracy of the ADNEX model, ROMA score, RMI I, and RMI IV, as well as two serum markers (CA125 and...
7.
Tozzi R, Bigardi S, Spagnol G, Ferrari F, Saccardi C, Noventa M, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409974
(1) Background: In 2018 FIGO reclassified tumors confined to the cervix larger than 4 cm as stage IB3. Although concurrent CTRT has been the standard of care and surgery the...
8.
Marchetti M, Spagnol G, Vezzaro T, Bigardi S, Tommasi O, Facchetti E, et al.
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335192
(1) Background: Endometrial carcinoma (EC) classified as no specific molecular profile (NSMP) represents a heterogeneous group with variable prognoses. This retrospective, single-center study aims to further stratify NSMP ECs to...
9.
Masatti L, Marchetti M, Pirrotta S, Spagnol G, Corra A, Ferrari J, et al.
Transl Res
. 2024 Aug;
273:104-114.
PMID: 39111726
Epithelial ovarian cancer is a significant global health issue among women. Diagnosis and treatment pose challenges due to difficulties in predicting patient responses to therapy, primarily stemming from gaps in...
10.
Spagnol G, Ghisoni E, Morotti M, Tommasi O, Marchetti M, Bigardi S, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000178
Immunotherapy, particularly the use of immune checkpoint inhibitors (ICIs), has shown limited efficacy in treating ovarian cancer (OC), possibly due to diverse T cell infiltration patterns in the tumor microenvironment....